Journal
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
Volume 34, Issue 5, Pages 395-397Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MPH.0b013e3182532078
Keywords
heart failure; cancer survivorship; late-effects
Categories
Funding
- Bankhead Coley New Investigator Research Award
- National Institutes of Health [HL072705, HL078522, HL053392, CA127642, CA068484, HD052104, AI50274, HD052102, HL087708, HL079233, HL004537, HL087000, HL007188, HL094100, HL095127, HD80002]
- Children's Cardiomyopathy Foundation
- University of Miami Women's Cancer Association
- Lance Armstrong Foundation
- Michael Garil Fund
- American Society of Hematology Trainee Research Award
Ask authors/readers for more resources
In 1977, a 5-year-old girl diagnosed with acute lymphoblastic leukemia was treated on Dana-Farber Cancer Institute Childhood Acute Lymphoblastic Leukemia Protocol 77-01, receiving a cumulative doxorubicin dose of 465 mg/m(2), cranial radiation, and other drugs. After being in continuous complete remission for 34 months, she developed heart failure and was treated with digoxin and furosemide. At 16 years of age, she was diagnosed and treated for dilated cardiomyopathy. Over the years, she continued to have bouts of heart failure, which became less responsive to treatment. At 36 years of age, she received a heart transplant. Six months later, she stopped taking her medications and suffered a sudden cardiac death.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available